VATARAKTA BEYOND GOUT: A CRITICAL NARRATIVE REVIEW AND PROPOSED MULTIDOMAIN CORRELATION FRAMEWORK

Background: Vatarakta, also known as Vatashonita, is described in Ayurveda as a disease arising from the pathological interaction of Vata and Rakta. Because classical descriptions include painful inflammatory manifestations of the extremities and joints, contemporary Ayurvedic literature frequently correlates Vatarakta with gout. Modern gout, however, is a crystal-deposition disease involving monosodium urate (MSU) crystals. Clinical resemblance between the two conditions does not necessarily establish diagnostic or pathophysiological equivalence. Objective: This review critically examines the relationship between Vatarakta and gout, identifies areas of meaningful overlap, clarifies the limitations of assuming equivalence, and proposes a multidomain framework for future validation research. Materials and Methods: A critical narrative review was conducted using classical Ayurvedic sources and contemporary literature on Vatarakta, gout, hyperuricemia, MSU crystal deposition, and crystal-induced arthropathies. Evidence was considered across Ayurvedic, clinical, biochemical, crystal-identification, and imaging domains, with particular attention to contemporary gout classification criteria and diagnostic recommendations. As this was a narrative review, formal meta-analysis and risk-of-bias assessment were not undertaken. Results: The reviewed literature indicates substantial phenotypic overlap between Vatarakta and gout, particularly in painful inflammatory manifestations of peripheral joints. However, hyperuricemia and non-specific joint inflammation are insufficient to establish gout. Identification of MSU crystals provides direct evidence of urate crystal deposition and is sufficient for classification under the 2015 ACR/EULAR criteria; in the absence of crystal confirmation, clinical, laboratory, and imaging domains contribute to classification. Ayurvedic concepts such as Vata-Rakta interaction and Avarana provide a coherent theoretical explanation of Vatarakta within Ayurveda, but their direct correspondence with specific biomedical mechanisms has not been established. Conclusion: Current evidence does not support treating Vatarakta and gout as universally synonymous. Gout is an important potential modern correlate of Vatarakta, but some presentations may clinically overlap with other arthropathies. A multidomain framework is proposed in which Ayurvedic phenotyping and modern rheumatological assessment are performed independently. Future prospective studies should use standardized Ayurvedic assessment, MSU crystal identification where clinically appropriate, and validated imaging methods to determine which Vatarakta phenotypes correspond to objectively established gout.

• Singh A, Mahajan S, Tiwari A, Mahajan K. A Conceptual Study on Vatarakta w.s.r. to Gouty Arthritis. AYUSHDHARA, 2024; 11(3): 70–78. Available from: https://ayushdhara.in/index.php/ayushdhara/article/view/1560.
• Preeti, Yadav R, Tewari AN. Review on Understanding and Management of Vatarakta W.S.R. to Hyperuricemia. International Journal of Health Sciences and Research, 2024; 14(8):           110–119. Doi:10.52403/ijhsr.20240814.
• Jaiswal P, Dachewar DA. A systemic literature review of Vatarakta and its management through Ayurveda w.s.r. to Gout. Sanjeevani Darshan National Journal of Ayurveda & Yoga, 2023; 1(2): 35–41. Doi:10.55552/SDNJAY.2023.1205.
• Neogi T, Jansen TLTA, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol, 2015; 67(10): 2557–2568. Doi:10.1002/art.39254.
• Richette P, Doherty M, Pascual E, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis., 2020; 79(1): 31–38. Doi:10.1136/annrheumdis-2019-215315.
• Narang R, Dalbeth N. Pathophysiology of gout. Semin Nephrol, 2020; 40(6): 550–563. Doi:10.1016/j.semnephrol.2020.12.001.
• Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet., 2016; 388(10055): 2039–2052. Doi:10.1016/S0140-6736(16)00346-9.
• Benn CL, Dua P, Gurrell R, et al. Physiology of hyperuricemia and urate-lowering treatments. Front Med (Lausanne), 2018; 5: 160. Doi:10.3389/fmed.2018.00160.
• Agnivesha. Charaka Samhita. Chikitsa Sthana, Vatarakta Chikitsa Adhyaya, Chapter 29, verses 5–29. Acharya YT, editor. Varanasi: Chaukhambha Sanskrit Sansthan, 2017; 627–641.
• Sushruta. Sushruta Samhita. Nidana Sthana, Vatavyadhi Nidana Adhyaya, Chapter 1, verses 41–45; Chikitsa Sthana, Mahavatavyadhi Chikitsa Adhyaya, Chapter 5, verses 1–17. Acharya YT, editor. Varanasi: Chaukhambha Orientalia, 2014; 263–265, 424–428.
• Agnivesha. Charaka Samhita. Chikitsa Sthana, Vatarakta Chikitsa Adhyaya, Chapter 29, verses 5–29. Acharya YT, editor. Varanasi: Chaukhambha Sanskrit Sansthan, 2017; 627–641.
• Agnivesha. Charaka Samhita. Chikitsa Sthana, Vatarakta Chikitsa Adhyaya, Chapter 29, verses 5–29. Acharya YT, editor. Varanasi: Chaukhambha Sanskrit Sansthan, 2017; 627–641.
• Sushruta. Sushruta Samhita. Nidana Sthana, Vatavyadhi Nidana Adhyaya, Chapter 1, verses 41–45; Chikitsa Sthana, Mahavatavyadhi Chikitsa Adhyaya, Chapter 5, verses 1–17. Acharya YT, editor. Varanasi: Chaukhambha Orientalia, 2014; 263–265, 424–428.
• Madhavakara. Madhava Nidana (Roga Vinischaya). Vatarakta Nidanam (Chapter 23). In: Shastri S, Upadhyaya Y, editors. Madhava Nidana with the ‘Madhukosha’ Commentary by Shrivijayarakshita and Srikanthadatta, and the ‘Vidyotini’ Hindi Commentary. Classic ed. Varanasi: Chaukhambha Prakashak; 2024. Verses 1–35. Pp. 495–510.
• Vagbhata. Ashtanga Hridaya, Nidana Sthana, Chapter 16 (Vatashonita Nidana). In: Hari Sastri Paradkar Vaidya, editor. Ashtanga Hridayam of Vagbhata with the Commentaries Sarvangasundara of Arunadatta and Ayurvedarasayana of Hemadri. Varanasi: Chaukhamba Sanskrit Sansthan, 2014; 537–543.
• Vagbhata. Ashtanga Sangraha. Vatashonita Nidanam (Chapter 16). In: Shivprasad Sharma, editor. Ashtanga Sangraha of Vriddha Vagbhata with Sasilekha Sanskrit Commentary by Indu. Varanasi: Chaukhambha Sanskrit Series Office, 2006.
• Bhavamishra. Bhāvaprakāśa (Madhyama Khaṇḍa, Vātarakta Adhikāra, Chapter 29, Verses 155-164). Srikantha Murthy KR, translator. Vol. 2. Varanasi: Chaukhambha Orientalia, 2010; 320.
• Narang R, Dalbeth N. Pathophysiology of gout. Semin Nephrol, 2020; 40(6): 550–563. Doi:10.1016/j.semnephrol.2020.12.001.
• Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet, 2016; 388(10055): 2039–2052. Doi:10.1016/S0140-6736(16)00346-9.
• Benn CL, Dua P, Gurrell R, et al. Physiology of hyperuricemia and urate-lowering treatments. Front Med (Lausanne), 2018; 5: 160. Doi:10.3389/fmed.2018.00160.
• Richette P, Doherty M, Pascual E, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis., 2020; 79(1): 31–38. Doi:10.1136/annrheumdis-2019-215315.
• Narang R, Dalbeth N. Pathophysiology of gout. Semin Nephrol, 2020; 40(6): 550–563. Doi:10.1016/j.semnephrol.2020.12.001.
• Dalbeth N, Merriman TR, Stamp LK. Gout. Lancet, 2016; 388(10055): 2039–2052. Doi:10.1016/S0140-6736(16)00346-9.
• Benn CL, Dua P, Gurrell R, et al. Physiology of hyperuricemia and urate-lowering treatments. Front Med (Lausanne), 2018; 5: 160. Doi:10.3389/fmed.2018.00160.
• Neogi T, Jansen TLTA, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheumatol, 2015; 67(10): 2557–2568. Doi:10.1002/art.39254.
• Richette P, Doherty M, Pascual E, et al. 2018 updated European League Against Rheumatism evidence-based recommendations for the diagnosis of gout. Ann Rheum Dis., 2020; 79(1): 31–38. Doi:10.1136/annrheumdis-2019-215315.
• Gessl I, Sakellariou G, Wildner B, Dejaco C, Duftner C, Karalilova R, et al. Systematic literature review to inform the EULAR recommendations for the use of imaging in crystal-induced arthropathies in clinical practice. Ann Rheum Dis., 2024; 83(9): 1208–1224. Doi:10.1136/ard-2023-225247.
• Filippucci E, Reginato A, Thiele R. Imaging of crystalline arthropathy in 2020. Best Pract Res Clin Rheumatol, 2020; 34(6): 101595. Doi:10.1016/j.berh.2020.101595.
• Singh A, Mahajan S, Tiwari A, Mahajan K. A Conceptual Study on Vatarakta w.s.r. to Gouty Arthritis. AYUSHDHARA, 2024; 11(3): 70–78. Available from: https://ayushdhara.in/index.php/ayushdhara/article/view/1560.
• Rosenthal AK, Ryan LM. Calcium Pyrophosphate Deposition Disease. N Engl J Med., 2016 Jun 30; 374(26): 2575-2584. Doi: 10.1056/NEJMra1511117.